UTRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
UTRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-25), Minerva Surgical's share price is $0.001. Minerva Surgical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-8.33. Therefore, Minerva Surgical's PE Ratio (TTM) for today is At Loss.
The historical rank and industry rank for Minerva Surgical's PE Ratio (TTM) or its related term are showing as below:
During the past 4 years, the highest PE Ratio (TTM) of Minerva Surgical was 22.37. The lowest was 0.00. And the median was 19.08.
Minerva Surgical's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.81. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-8.33.
As of today (2024-05-25), Minerva Surgical's share price is $0.001. Minerva Surgical's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-8.33. Therefore, Minerva Surgical's PE Ratio without NRI for today is At Loss.
During the past 4 years, Minerva Surgical's highest PE Ratio without NRI was 22.37. The lowest was 0.00. And the median was 19.08.
Minerva Surgical's EPS without NRI for the three months ended in Sep. 2023 was $-0.81. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-8.33.
During the past 3 years, the average EPS without NRI Growth Rate was 16.00% per year.
During the past 4 years, Minerva Surgical's highest 3-Year average EPS without NRI Growth Rate was 16.00% per year. The lowest was 16.00% per year. And the median was 16.00% per year.
Minerva Surgical's EPS (Basic) for the three months ended in Sep. 2023 was $-0.81. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-8.33.
The historical data trend for Minerva Surgical's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minerva Surgical Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
PE Ratio (TTM) | N/A | N/A | At Loss | At Loss |
Minerva Surgical Quarterly Data | |||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
PE Ratio (TTM) | Get a 7-Day Free Trial | At Loss | At Loss | At Loss | At Loss | At Loss |
For the Medical Devices subindustry, Minerva Surgical's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Minerva Surgical's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Minerva Surgical's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Minerva Surgical's PE Ratio (TTM) for today is calculated as
PE Ratio (TTM) | = | Share Price | / | Earnings per Share (Diluted) (TTM) |
= | 0.001 | / | -8.330 | |
= | At Loss |
Minerva Surgical's Share Price of today is $0.001.
Minerva Surgical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PE Ratio (TTM) | = | Market Cap | / | Net Income |
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Minerva Surgical (OTCPK:UTRS) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Thank you for viewing the detailed overview of Minerva Surgical's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Cohen | director | C/O ACCELMED, 848 BRICKELL AVE, #901, MIAMI FL 33131 |
Accelmed Partners Ii L.p. | 10 percent owner | 2875 NE 191ST, SUITE 500, AVENTURA FL 33180 |
New Enterprise Associates 13 Lp | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Uri Geiger | director, 10 percent owner | 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815 |
Todd Usen | director, officer: Chief Executive Officer | C/O MINERVA SURGICAL, INC., 4255 BURTON DRIVE, SANTA CLARA CA 95054 |
Derrick Sung | director | C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103 |
David M Clapper | director, officer: President and CEO | 3003 TASMAN DRIVE, SANTA CLARA CA 95054 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Jaffe Ross A Md | director | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Evgueni V. Skalnyi | officer: VP Medical Affairs | C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054 |
Dominique J. Filloux | officer: COO | C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054 |
Joel R Jung | officer: CFO | 1401 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
Niquette L. Hunt | director | SOLITON, INC., 5304 ASHBROOK DRIVE, HOUSTON TX 77081 |
Jill Anderson | director | 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095 |
Nea Partners 13, Limited Partnership | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
From GuruFocus
By Value_Insider Value_Insider • 11-21-2022
By Stock market mentor Stock market mentor • 01-03-2023
By GuruFocusNews GuruFocusNews • 05-10-2022
By GuruFocusNews GuruFocusNews • 04-26-2022
By PurpleRose PurpleRose • 07-21-2022
By PurpleRose PurpleRose • 08-03-2022
By GuruFocusNews GuruFocusNews • 01-04-2022
By Value_Insider Value_Insider • 11-07-2022
By Tiesvg Tiesvg • 12-27-2022
By PurpleRose PurpleRose • 07-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.